Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for Ménière's disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for Ménière's is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Anecdotal reports and very small case series describe symptomatic relief in some patients. There are no randomized controlled trials. Standard management of Ménière's includes low-sodium diet, diuretics, betahistine (where available), intratympanic dexamethasone or gentamicin for refractory cases, and surgical options (endolymphatic sac decompression, labyrinthectomy) for severe disease.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment (placement near the ear, mastoid)
- Bruising and tenderness near the ear and upper neck for 5 to 10 days
- Itching and irritation at bite sites
- Local skin infection or, rarely, Aeromonas infection (heightened concern near ear)
- Allergic reaction to leech saliva (uncommon)
- Temporary worsening of vertigo, tinnitus, or aural fullness for 1 to 2 days
- Small permanent scars at bite sites
- Wer dies nicht in Betracht ziehen sollte
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with active otitis externa or media
- Patients with vestibular schwannoma or other retrocochlear pathology not yet evaluated
- Patients with severe debilitating vertigo who may benefit from intratympanic or surgical intervention
- Patients with a weakened immune system
- Was Sie Ihren Kliniker fragen sollten
- Have I had a full ENT and audiometric evaluation, and ruled out other vestibular conditions?
- Have I tried low-sodium diet, diuretics, and betahistine?
- Have I been offered intratympanic dexamethasone or gentamicin for refractory disease?
- What evidence supports leech therapy for Ménière's disease specifically?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the realistic chance of benefit, and for how long?
- What is the cost?
- Wann dringende medizinische Versorgung suchen
- Sudden hearing loss in one or both ears (sudden sensorineural hearing loss is an emergency)
- Sudden severe vertigo with neurologic symptoms — weakness, numbness, double vision, dysarthria (possible stroke)
- Severe ear pain, drainage, or fever (otitis or mastoiditis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Spreading redness or pus near the ear (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for Ménière's disease.
- Anecdotal reports do NOT establish efficacy beyond placebo for an episodic, fluctuating condition.
- Mechanism rationale does NOT establish clinical efficacy.
- Leech therapy will NOT cure Ménière's disease or prevent attacks.
- Leech therapy is not a substitute for ENT/otology evaluation and evidence-based therapy.
Sicherheits-Querverweise
Clinical Profile
- Category
- ent
- ICD-10
- H81.01, H81.02, H81.03
- Safety tier
- medium
Evidence Summary
No controlled clinical trial of leech therapy for Ménière's disease exists; the evidence is anecdotal at best and any use is investigational and mechanistic only. A proposed mechanism involves reduction of endolymphatic pressure through systemic effects on fluid dynamics, but this is unproven. Standard management (low-sodium diet, betahistine, diuretics, intratympanic dexamethasone or gentamicin, vestibular rehabilitation, endolymphatic sac surgery) remains primary. Leech therapy is only an exploratory adjunct under ENT supervision.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Cakir BO et al. (2019)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute vertiginous crisis (treat acutely first)
- Recent (<3 months) ear surgery
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.
Meniere's Disease (Vestibular Attack Frequency)
Investigational adjunct for vestibular attack frequency reduction in definite Meniere's disease per AAO-HNS 2015 criteria; case-series evidence.